Abstract
Interleukin 17 (IL-17) plays pivotal role in the pathogenesis of psoriasis. In a previous study, we identified a locus in the IL17F gene that is associated with psoriasis, the IL17F rs763780 (His161Arg) T/C variant. The current study aimed to elucidate the association between this polymorphism and psoriasis, and to determine its effect on serum levels of cytokine. A total of 116 psoriasis patients and 97 healthy volunteers were recruited. Genotyping analysis was performed using quantitative polymerase chain reaction, and serum levels of cytokine were measured using a multiplex immunoassay. The IL17F His161Arg polymorphism was significantly associated with psoriasis based on the genotype and allele analyses. Psoriasis patients harbouring the mutant allele had significantly increased serum levels of IL-17F. Our results suggest that this polymorphism is a potential risk locus for psoriasis and that it results in a direct increase in IL-17F production.
Highlights
Interleukin 17 (IL-17) plays pivotal role in the pathogenesis of psoriasis
Our study revealed the rs763780 (7488 T/C) psoriasis susceptibility single nucleotide polymorphism (SNP) in the IL17F gene on chromosome 6, which encodes interleukin-17F (IL-17F)[7]
Our study reveals an association between the IL17F His161Arg variant and psoriasis risk, and its effects on serum levels of cytokines in this population
Summary
Interleukin 17 (IL-17) plays pivotal role in the pathogenesis of psoriasis. In a previous study, we identified a locus in the IL17F gene that is associated with psoriasis, the IL17F rs763780 (His161Arg) T/C variant. Our study revealed the rs763780 (7488 T/C) psoriasis susceptibility single nucleotide polymorphism (SNP) in the IL17F gene on chromosome 6, which encodes interleukin-17F (IL-17F)[7] This is a missense mutation that results in a histidine-to-arginine substitution at amino acid 161 (His161Arg). The levels of IL-17A and IL-17F are increased in the lesional skin and blood of patients with psoriasis[14] Based on these investigations, biological agents targeting the IL-17 pathway, including secukinumab and ixekizumab, have been approved, and have contributed to the breakthrough in the treatment of psoriasis[15,16]. We aimed to study the association between the IL17F His161Arg polymorphism and the clinical manifestations of psoriasis and to determine its effect on serum levels of cytokine. Our study reveals an association between the IL17F His161Arg variant and psoriasis risk, and its effects on serum levels of cytokines in this population
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
